PMID: 11902116Mar 21, 2002Paper

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

Journal of Neurochemistry
Ken IkedaYoshihisa Kuwana

Abstract

Adenosine A2A receptors are abundant in the caudate-putamen and involved in the motor control in several species. In MPTP-treated monkeys, A2A receptor-blockade with an antagonist alleviates parkinsonian symptoms without provoking dyskinesia, suggesting this receptor may offer a new target for the antisymptomatic therapy of Parkinson's disease. In the present study, a significant neuroprotective effect of A2A receptor antagonists is shown in experimental models of Parkinson's disease. Oral administration of A2A receptor antagonists protected against the loss of nigral dopaminergic neuronal cells induced by 6-hydroxydopamine in rats. A2A antagonists also prevented the functional loss of dopaminergic nerve terminals in the striatum and the ensuing gliosis caused by MPTP in mice. The neuroprotective property of A2A receptor antagonists may be exerted by altering the packaging of these neurotoxins into vesicles, thus reducing their effective intracellular concentration. We therefore conclude that the adenosine A2A receptor may provide a novel target for the long-term medication of Parkinson's disease, because blockade of this receptor exerts both acutely antisymptomatic and chronically neuroprotective activities.

Citations

Nov 19, 2004·European Journal of Nuclear Medicine and Molecular Imaging·R M MorescoF Fazio
Apr 29, 2008·Purinergic Signalling·Marek CieślakAndrzej Wojtczak
Mar 26, 2011·Purinergic Signalling·Maria Letizia TrincavelliClaudia Martini
May 16, 2012·Current Neurology and Neuroscience Reports·Patrick Hickey, Mark Stacy
Apr 23, 2009·Neurotoxicity Research·Krystyna GołembiowskaKatarzyna Kamińska
May 24, 2013·Drugs·Rosselle Dungo, Emma D Deeks
Nov 6, 2003·Journal of Chemical Neuroanatomy·Khan Shoeb ZafarFakhrul Islam
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Peter A LeWitt, Danette C Taylor
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacobus P PetzerCornelis J Van der Schyf
Oct 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Phillip M Rappold, Kim Tieu
Mar 12, 2003·Bioorganic & Medicinal Chemistry·Jacobus P PetzerNeal Castagnoli
Aug 4, 2012·ACS Chemical Neuroscience·Brian C Shook, Paul F Jackson
Sep 19, 2009·Cell Death and Differentiation·D BoisonB B Fredholm
Jan 25, 2003·The European Journal of Neuroscience·Fernando BerrenderoOlga Valverde
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Bertil B FredholmJean-Marie Vaugeois
Apr 23, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shuang-Shuang DaiJiang-Fan Chen
May 25, 2011·Drug Design, Development and Therapy·Patrick Hickey, Mark Stacy
Feb 23, 2011·International Journal of Molecular Sciences·Elizabeth A MazzioKaram F A Soliman
Dec 3, 2015·Expert Review of Neurotherapeutics·Ruxandra Julia Vorovenci, Angelo Antonini
Nov 6, 2009·Expert Opinion on Investigational Drugs·Annalisa Pinna
Jan 19, 2016·Bioorganic & Medicinal Chemistry Letters·Sarel J RobinsonAnna C U Lourens
Nov 5, 2015·Cerebral Cortex·Diana G FerreiraLuísa V Lopes
Aug 12, 2005·Journal of Neurochemistry·Josep SauraJoan Serratosa
Apr 15, 2005·Neurological Research·Susan A Masino, Christopher G Dulla
Jun 10, 2015·SAR and QSAR in Environmental Research·E PourbasheerM R Ganjali
Nov 9, 2011·The International Journal of Neuroscience·Robert A Hauser
Feb 22, 2011·Expert Opinion on Drug Metabolism & Toxicology·Nikoletta SzabóLászló Vécsei
Nov 27, 2007·European Journal of Pharmacology·Mariangela GalluzzoPatrizia Popoli
Sep 12, 2009·Atencion primaria·Rafael Franco
Jan 16, 2003·Science's STKE : Signal Transduction Knowledge Environment·Elena Bastia, Michael A Schwarzschild
Oct 1, 2005·Journal of Receptor and Signal Transduction Research·Yuting Tang, Keith T Demarest
Mar 2, 2005·Pharmacology & Therapeutics·Kui XuMichael Schwarzschild

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.